Vertex Pharmaceuticals Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Vertex Pharmaceuticals is de winst gegroeid met een gemiddeld jaarlijks percentage van 1.4%, terwijl de Biotechs industrie de winst jaarlijks groeide met 7.7%. De inkomsten zijn gegroeid met een gemiddelde van 17.6% per jaar.

Belangrijke informatie

1.4%

Groei van de winst

1.5%

Groei van de winst per aandeel

Biotechs Groei van de industrie	11.5%
Inkomstengroei	17.6%
Rendement op eigen vermogen	-3.1%
Nettomarge	-4.5%
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Opbrengsten en kosten

Hoe Vertex Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

LSE:0QZU Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven
30 Sep 24	10,626	-480	1,456
30 Jun 24	10,337	-490	1,348
31 Mar 24	10,185	4,019	1,238
31 Dec 23	9,869	3,620	1,137
30 Sep 23	9,654	3,470	1,035
30 Jun 23	9,505	3,365	1,018
31 Mar 23	9,208	3,260	971
31 Dec 22	8,931	3,322	945
30 Sep 22	8,701	3,273	933
30 Jun 22	8,350	3,195	884
31 Mar 22	7,948	2,451	863
31 Dec 21	7,574	2,342	840
30 Sep 21	7,130	2,176	797
30 Jun 21	6,684	1,992	783
31 Mar 21	6,415	2,762	780
31 Dec 20	6,206	2,712	771
30 Sep 20	5,991	2,691	754
30 Jun 20	5,403	2,081	729
31 Mar 20	4,819	1,511	694
31 Dec 19	4,163	1,177	659
30 Sep 19	3,620	2,144	616
30 Jun 19	3,454	2,215	594
31 Mar 19	3,265	2,155	575
31 Dec 18	3,048	2,096	558
30 Sep 18	2,829	647	539
30 Jun 18	2,623	415	523
31 Mar 18	2,415	226	513
31 Dec 17	2,489	263	496
30 Sep 17	2,296	196	471
30 Jun 17	2,131	259	457
31 Mar 17	2,019	177	441
31 Dec 16	1,702	-112	433
30 Sep 16	1,661	-219	419
30 Jun 16	1,557	-275	413
31 Mar 16	1,292	-399	396
31 Dec 15	1,032	-556	377
30 Sep 15	759	-659	359
30 Jun 15	628	-734	334
31 Mar 15	600	-704	317
31 Dec 14	580	-738	305
30 Sep 14	787	-582	300
30 Jun 14	830	-530	308
31 Mar 14	1,002	-428	338
31 Dec 13	1,212	-504	356

Kwaliteitswinsten: 0QZU is momenteel verliesgevend.

Groeiende winstmarge: 0QZU is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: 0QZU is verlieslatend, maar heeft de verliezen de afgelopen 5 jaar met een snelheid van 1.4% per jaar verminderd.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van 0QZU over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: 0QZU is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( -18.2% ).

Rendement op eigen vermogen

Hoge ROE: 0QZU heeft een negatief Return on Equity ( -3.07% ), omdat het momenteel verliesgevend is.

Vertex Pharmaceuticals Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Third quarter 2024 earnings released: EPS: US$4.05 (vs US$4.01 in 3Q 2023)

Vertex Pharmaceuticals Incorporated to Report Q3, 2024 Results on Nov 04, 2024

Second quarter 2024 earnings released: US$13.92 loss per share (vs US$3.55 profit in 2Q 2023)

Vertex Pharmaceuticals Incorporated to Report Q2, 2024 Results on Aug 01, 2024

First quarter 2024 earnings released: EPS: US$4.26 (vs US$2.72 in 1Q 2023)

Vertex Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 06, 2024

Recent updates

Third quarter 2024 earnings released: EPS: US$4.05 (vs US$4.01 in 3Q 2023)

Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024

Vertex Pharmaceuticals Incorporated to Report Q3, 2024 Results on Nov 04, 2024

Second quarter 2024 earnings released: US$13.92 loss per share (vs US$3.55 profit in 2Q 2023)

Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024

Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-To-Severe Acute Pain

Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Marketing Authorization for Trikafa® for People with Cystic Fibrosis Aged 2 Years and Older with Certain Rare Mutations

Vertex Pharmaceuticals Incorporated to Report Q2, 2024 Results on Aug 01, 2024

Vertex Pharmaceuticals, Inc. Announces Positive Results from Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders.

Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director

Vertex Pharmaceuticals Incorporated Re-Iterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$4.26 (vs US$2.72 in 1Q 2023)

Vertex Pharmaceuticals Announces European Commission Approval for KALYDECO to Treat Infants with Cystic Fibrosis Ages 1 Month and Older

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

Vertex Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 06, 2024

Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 15, 2024

Vertex Pharmaceuticals Incorporated Announces New Drug Submission for Exagamglogene Autotemcel (Exa-Cel) Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Receives CHMP Positive Opinion for KALYDECO for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Positive Results from Pivotal Trials of Vanza Triple Combination Treatment for Cystic Fibrosis

Vertex Pharmaceuticals Incorporated Provides Product Revenue Guidance for the Full Year 2024

Full year 2023 earnings released: EPS: US$14.05 (vs US$12.97 in FY 2022)

Vertex Announces Positive Results from the VX-548 Phase 3 Program for the Treatment of Moderate-To-Severe Acute Pain

Vertex Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 05, 2024

Vertex Pharmaceuticals Incorporated Announces US FDA Approval of CASGEVY™ (Exagamglogene Autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Kingdom of Saudi

Vertex Pharmaceuticals Incorporated Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States

Vertex Pharmaceuticals Incorporated Appoints Nancy Thornberry to Its Board of Directors as an Independent Director

Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older

Vertex Pharmaceuticals Incorporated Announces European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5

Vertex Pharmaceuticals Incorporated Announces United Kingdom Medicines and Healthcare Products Regulatory Agency Granted Conditional Marketing Authorization for CASGEVY

Third quarter 2023 earnings released: EPS: US$4.01 (vs US$3.63 in 3Q 2022)

Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Market Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With at Least One F508del Mutation

Vertex Pharmaceuticals Incorporated to Report Q3, 2023 Results on Nov 06, 2023

Vertex Pharmaceuticals Incorporated Appoints Michel Lagarde to Its Board of Directors

Vertex Pharmaceuticals Incorporated Receives Chmp Positive Opinion for Kaftrio® (Ivacaftor/Tezacaftor/Elexacaftor) in Combination with Ivacaftor for Children with Cystic Fibrosis Ages 2 Through 5

Vertex Pharmaceuticals Incorporated Appoints E. Morrey Atkinson, Ph.D., as Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations

Vertex Pharmaceuticals Incorporated Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine

Second quarter 2023 earnings released: EPS: US$3.55 (vs US$3.17 in 2Q 2022)

Vertex Pharmaceuticals Incorporated Announces European Commission Approval for ORKAMBI® (Lumacaftor/Ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 1 to <2 Years Old

Insufficient new directors

Vertex Pharmaceuticals Incorporated Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions

Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

First quarter 2023 earnings released: EPS: US$2.72 (vs US$2.99 in 1Q 2022)

Full year 2022 earnings released: EPS: US$12.97 (vs US$9.09 in FY 2021)

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) announces an Equity Buyback for $3,000 million worth of its shares.

Vertex Pharmaceuticals Incorporated to Report Q4, 2022 Results on Feb 07, 2023

Vertex Pharmaceuticals Incorporated Announces to Present New Data on its Portfolio of Cystic Fibrosis Medicines at 2022 North American Cystic Fibrosis Conference

Third quarter 2022 earnings released: EPS: US$3.63 (vs US$3.30 in 3Q 2021)

Vertex Pharmaceuticals Incorporated Revises Revenue Guidance for the Fiscal 2022

Vertex Pharmaceuticals Incorporated to Report Q3, 2022 Results on Oct 27, 2022

Vertex Pharmaceuticals Incorporated Advances Program Targeting Alpha-1 Antitrypsin Deficiency

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

Vertex Pharmaceuticals Incorporated Appoints Jonathan Biller as Chief Legal Officer, Effective September 19, 2022

Vertex Pharmaceuticals Incorporated Appoints Jonathan Biller as Chief Legal Officer, Effective September 19, 2022

Vertex Announces U.S. FDA Approval for Orkambi® (Lumacaftor/Ivacaftor) in Children with Cystic Fibrosis Ages 12 to <24 Months

Second quarter 2022 earnings released: EPS: US$3.17 (vs US$0.26 in 2Q 2021)

Vertex Pharmaceuticals Incorporated Reports Unaudited Intangible Asset Impairment Charge for the Three Months Ended June 30, 2022

Vertex Advances VX-548 in Acute and Neuropathic Pain

Vertex Pharmaceuticals Incorporated to Report Q2, 2022 Results on Aug 04, 2022

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into a definitive agreement to acquire ViaCyte, Inc. from Sanderling Ventures, RA Capital Management, L.P., The Invus Group, LLC, Asymmetry Ventures LLC and others for approximately $320 million.

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into a definitive agreement to acquire ViaCyte, Inc. from Sanderling Ventures, RA Capital Management, L.P., The Invus Group, LLC, Asymmetry Ventures LLC and others for approximately $320 million.

Vertex Announces FDA Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes

Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference

Vertex Pharmaceuticals Incorporated Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA